Anti-PD-L1 CSR T cells in Recurrent Glioblastoma Multiforme

Phase 1, open-label, single-arm trial of Anti-PD-L1 CSR T cells in glioblastoma multiforme (GBM), sponsored by Beijing Sanbo Brain Hospital. Primary endpoint: Number of Adverse Events related to CSR T cell infusion at 2 years. Status: unknown.